
Sander Lak Is Back! The Sies Marjan Designer Will Debut an Eponymous Collection in Paris
Sanderlak, as he's named it, is a conceptual label rooted in what Lak describes as his nomadic childhood. 'My upbringing was extremely transient,' he says, 'I lived all over the world, and applying that same way of thinking to creating makes a lot of sense to me.' The result will be at least two, possibly more, collections a year of 'really wearable clothes—shirts, pants, jackets, coats, a little bit of tailoring,' that are all inspired by a specific place—it could be a city, it could be an entire country—of Lak's choosing.
'The original idea was to do a company without any real, actual roots, but the logistics of that were impossible,' he laughs. 'What I will be doing is looking at what the textures are, what the colors are of a place, and that will be shaping what the clothes will be.' The concept goes beyond local inspirations; he's set himself some ground rules, which include sourcing material and vintage garments only from the location of his focus, organizing collaborations and capsule collections with companies native to that place, and booking local photographers and models for shoots.
'Creativity happens from limitation. I've worked for amazing people and I've had freedom, but you can get a little bit lazy with the idea that anything is possible. I like the idea of parameters. I feel the work comes out in really surprising ways because I keep pushing myself.'
Sies Marjan, fall 2016 ready-to-wear
Photo: Courtesy of Sies Marjan
Sies Marjan, spring 2018 ready-to-wear
Photo: Luca Tombolini / Indigital.tv
Sies Marjan, fall 2018 ready-to-wear
Photo: Marcus Tondo / Indigital.tv
Sies Marjan, spring 2019 ready-to-wear
Photo: Yannis Vlamos / Indigital.tv
Sies Marjan, spring 2020 ready-to-wear
Photo: Filippo Fior / Gorunway.com
Sies Marjan, fall 2020 ready-to-wear
Photo: Courtesy of Sies Marjan
Backed by angel investors, Lak has declined to share the region he's leaning into for launch, preferring to save that information for his Paris debut, but one thing is for certain: he won't be moving on every season. He'll 'stay' a year in a place, maybe more. 'I like the idea of continuing a conversation, instead of talking about Picasso one day and, I don't know, Greece the next. I find that really disconnected. I like it when an artist works on something and perfects it and goes deeper into it, and then maybe goes elsewhere. This exploration, this deeper search for things, is something I was really hungry for.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 days ago
- Yahoo
Novartis to pay Matchpoint up to $1 billion to develop anti-inflammatory therapies
(Reuters) -Swiss drugmaker Novartis will pay up to $1 billion to U.S. biotech Matchpoint Therapeutics to develop oral drugs for several inflammatory diseases. Matchpoint said on Thursday it will use its technology to develop drugs that block the activity of a specific protein, helping to lower the production of inflammation-causing signals. The company will lead the research and drug development process, using the funding from Novartis. If Novartis exercises its option to exclusively license the program, the drugmaker will have global rights to develop and commercialize all products resulting from the collaboration. Matchpoint said it will receive up to $60 million in upfront payment and research funding, with up to $1 billion in total potential payments, including option exercise fee, and development and commercial milestones. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 days ago
- Yahoo
Novartis to pay Matchpoint up to $1 billion to develop anti-inflammatory therapies
(Reuters) -Swiss drugmaker Novartis will pay up to $1 billion to U.S. biotech Matchpoint Therapeutics to develop oral drugs for several inflammatory diseases. Matchpoint said on Thursday it will use its technology to develop drugs that block the activity of a specific protein, helping to lower the production of inflammation-causing signals. The company will lead the research and drug development process, using the funding from Novartis. If Novartis exercises its option to exclusively license the program, the drugmaker will have global rights to develop and commercialize all products resulting from the collaboration. Matchpoint said it will receive up to $60 million in upfront payment and research funding, with up to $1 billion in total potential payments, including option exercise fee, and development and commercial milestones. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
04-06-2025
- Yahoo
XTERA Introduces Managed Wealth-Growth Platform
XTERA New York City, NY, June 04, 2025 (GLOBE NEWSWIRE) --XTERA, a new financial platform built for everyday individuals, has launched its professionally managed wealth-building service, designed to provide steady, daily returns without requiring users to become financial experts or take on unnecessary risk. In a time when side hustles and high-risk trading platforms dominate personal finance conversations, XTERA offers a more practical alternative: a way to grow money in the background, with oversight from experienced professionals and complete transparency. 'We built XTERA for people who are tired of having to choose between financial growth and free time,' said a spokesperson for XTERA. 'Our goal is to give users a simple way to participate in modern financial markets without needing to constantly check charts or learn investing on their own.' How It Works: XTERA allocates user funds into a diversified portfolio, managed by real traders with expertise in today's key sectors—such as AI, Web3, and other emerging industries. Users do not need to take any active role. Returns are calculated daily, and members have access to a live dashboard to track performance in real time. Funds are accessible at all times with no holding periods, penalties, or lock-ins. XTERA is available exclusively within The Code, a private community focused on accessible and sustainable financial tools. An invite is required to join, keeping the platform focused on members who are genuinely looking for long-term, stable financial growth. Built for Regular People XTERA is specifically designed for individuals with full-time jobs, family commitments, or limited bandwidth to explore complex financial products. It requires no prior investing experience, and the setup is simple. Most importantly, it doesn't rely on users spending extra hours working to earn more. About XTERA XTERA is a financial platform designed to give everyday people a smarter, more accessible way to grow their wealth. Built exclusively for members of The Code, it offers daily earning potential through expertly managed portfolios, without the stress of doing it all yourself. With real traders behind the scenes and full transparency through live dashboards, XTERA puts the user in control while doing the hard work for them. No lock-ins. No complicated setups. Just a modern, flexible path to building your financial the community Number: 4047 LLC 2025Richmond Hill, P.O. Box 2897, Kingstown St. Vincent and The Grenadines Prisha Elgouharipr@ Attachment XTERA CONTACT: Company Number: 4047 LLC 2025 Richmond Hill, P.O. Box 2897, Kingstown St. Vincent and The Grenadines Prisha Elgouhari pr@ in to access your portfolio